Clinical trials of monoclonal antibodies against interleukin-23, such as Ustekinumab and risankizumab, have shown efficacy and safety in IBD patients (Feagan et al. 2017, 2016; Sandborn et al. 2012; Sands et al. 2017). The gene discussed is IL37; the disease is inflammatory bowel disease.